49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01781611 (ClinicalTrials.gov) | February 2013 | 2/1/2013 | Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE) | Dipyridamole Assessment for Flare Reduction in SLE | Systemic Lupus Erythematosus | Drug: extended release dipyridamole 200mg/aspirin 25mg;Drug: 81mg aspirin | Oklahoma Medical Research Foundation | NULL | Terminated | 18 Years | 70 Years | All | 18 | N/A | United States |
| 2 | NCT00371501 (ClinicalTrials.gov) | June 2006 | 1/9/2006 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus | Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial | Atherosclerosis;Thromboembolism;Systemic Lupus Erythematosus | Drug: Rosuvastatin;Drug: placebo;Drug: aspirin | Tuen Mun Hospital | AstraZeneca | Completed | 18 Years | N/A | Both | 72 | Phase 4 | Hong Kong |
| 3 | NCT00731302 (ClinicalTrials.gov) | April 2005 | 5/8/2008 | Aspirin Resistance in Systemic Lupus Erythematosus (SLE) | Vascular Damage in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: aspirin and meloxicam | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | All | 70 | Phase 1 | United States |
| 4 | NCT00054938 (ClinicalTrials.gov) | March 2003 | 13/2/2003 | Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) | A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study | Systemic Lupus Erythematosus;Lupus | Drug: pravastatin;Drug: aspirin;Drug: ramipril;Drug: Vitamins: B6, B12, and folate;Behavioral: heart health educational program | Brigham and Women's Hospital | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | N/A | Both | 150 | Phase 2 | United States |